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Tissues such as the lung, skin, intestinal
epithelium, and reproductive tract serve
as a barricade against pathogen exposure
for the entire body. Specifically within the
skin and mucosal tissues, a population
of resident CD8 T cells plays a salient
role in the protection against infection.
Resident-memory CD8 T cells (TRM) are
a long-lived subset of memory CD8 T
cells that do not re-circulate after tak-
ing up residence in the tissues. Tradi-
tionally memory CD8 T cells were con-
ceptually divided into two subsets central
(TCM) and effector (TEM) memory where
TCM preferentially localized within sec-
ondary lymphoid tissues (SLO) and TEM
circulated throughout the peripheral tis-
sues. While the concept of TCM and TEM
has been considerably explored, memory
CD8 T cells found within barrier tissues
do not totally fit within the TCM/TEM
paradigm. Through the study of circu-
lating CD8 T cells, our understanding of
memory CD8 T cells has grown tremen-
dously in the last 25 years. We now under-
stand that it is not sufficient to sim-
ply generate large numbers of circulat-
ing memory CD8 T cells in order to
enhance protection against localized infec-
tion. Developing clinical strategies that
can enhance protection against mucosal
pathogens will require a clear understand-
ing of how memory CD8 T cells are gener-
ated and maintained within barrier tissues
at the sites of initial pathogen exposure. We
will outline our current understanding of
TRM in respect to their generation, func-
tional importance, and how future studies
must shed light on how we can exploit TRM
to develop the next generation of effective
vaccines.
GENERATION OF TISSUE-RESIDENT-
MEMORY CD8 T CELLS
CD8 T cells are primed within tissue drain-
ing lymph nodes and lymphoid tissues.
Once primed, CD8 T cells receive tissue-
specific signals that allow them entry into
tissues, which at steady-state are normally
non-permissive to T cell migration (1).
Upon entry into mucosal or skin tissues
CD8 T cells take up residence and do not re-
circulate (2, 3). For T cells to enter the small
intestine the integrin α4β7 and chemokine
receptor CCR9 are important (4, 5). α4β7
and CCR9 expression is induced by den-
dritic cell-derived signals like the vitamin
A metabolite retinoic acid (6). α4β7 is
transiently expressed and the timing of its
expression correlates with the window of
opportunity for T cell migration into the
small intestine (2, 4, 5). Primed T cells
that enter mucosal tissues differentiate into
TRM in response to tissue-derived signals,
not limited to but including TGF-β and
IL-15 (5, 7). Tissue-derived signals like
TGF-β and IL-15 are not uniquely con-
fined to barrier tissues, as their availability
is also important for circulating CD8 T
cells. TRM originate from KLRG1− effec-
tor cells, are not terminally differentiated,
however, express lower levels of CD127
and CD122 than circulating memory CD8
T cells (7, 8). While TRM share a com-
mon naïve precursor with blood and SLO
memory cells they are inherently differ-
ent from their circulating counterparts (9).
Unlike circulating memory CD8 T cells,
TRM maintain expression of CD69 and
elevated levels of Granzyme B, attributes
akin to effector cells (2, 10, 11). Gener-
ation of TRM is dependent on CD69 as
overexpression S1pr1 or deletion of CD69
in CD8 T cells limits TRM formation (7,
12). TRM also upregulate the integrin sub-
unit CD103 whereas circulating memory
CD8 T cells remain CD103− (2, 8). A
qualitative feature that distinguishes cir-
culating TCM and TEM from TRM is that
regardless of infection or anatomical loca-
tion TRM share a signature of core gene
transcripts (7). Within this signature are
genes involved in chemotaxis, adhesion,
and co-stimulation. Expression of some
genes associated with circulating memory
cells are decreased, e.g., Eomes, S1pr1, and
Ly6C. The signaling events that regulate
the transcriptional programing of TRM is
unknown.
mTOR AND TRM FORMATION
The mammalian target of rapamycin
(mTOR) kinase is a central regulator
of many cell processes, including sur-
vival, differentiation, and proliferation. It
orchestrates cellular responses to external
and internal environmental cues. Signaling
through the mTOR pathway is an impor-
tant event for memory formation (13).
During each stage of T cell priming, mTOR
is activated i.e., TCR/CD28/IL-12. How-
ever, inhibiting mTOR in effector CD8
T cells increases the number of memory
CD8 T cells in the circulation by increas-
ing the number of effector CD8 T cells that
are CD127hiKLRG1−. This suggests that
while mTOR is needed early during activa-
tion for effector formation, at some point
during the effector phase mTOR could
be attenuated or turned off in order for
effector cells to progress toward memory
differentiation.
We recently reported that accumulation
of CD8 T cells in the small intestine and
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FRT is critically dependent on prolonged
mTOR signaling (14). We showed that
blocking mTOR signaling during the effec-
tor phase inhibits the accumulation of
effector CD8 T cells in the mucosa thereby
limiting TRM formation. This suggests that
mTOR controls signals that either direct
the migration of CD8 T cells into these
barrier tissues or influences their survival.
More importantly, because one naive CD8
T cell can give rise to memory in both the
SLO and mucosal, our observations indi-
cate that mTOR may regulate the diver-
gence between circulating and resident-
memory CD8 T cells. It is also possible
that mTOR controls the context in which
memory precursors receive signals from
cytokines and growth factors. Circulating
memory CD8 T cells interact with differ-
ent stromal and hematopoietic cells than
tissue-resident-memory CD8 T cells and
this could influence their overall func-
tion and survival. For example, IL-15 is
an important homeostatic cytokine for
memory CD8 T cells, received through a
contact-dependent mechanism known as
trans-presentation, and for TRM forma-
tion (5, 15). Within the memory CD8 T
cell populations both IL-15-dependent and
IL-15 independent populations have been
described. mTOR can be activated by IL-15
and inhibition of mTOR leads to a pre-
dominantly IL-15 independent memory
population (16, 17).
Many cell types within different tis-
sues produce IL-15 and as a result TRM
may receive IL-15 signals more frequently
than circulating TEM that may only receive
transient IL-15 signals when they circulate
through the tissues. While TGF-β induces
apoptosis in circulating effector CD8 T
cells, TRM generated from effector CD8 T
cells rely on TGF-β signals (7, 18). Since
mTOR has broad affects on cell physiol-
ogy and is activated in effector CD8 T cells,
mTOR may be central in regulating the
unique transcriptional program in TRM.
mTOR signaling is mediated by two dis-
tinct complexes, mTORC1 and mTORC2
that control responses to environmental
cytokine milieus (13). In the absence of
mTOR, T cells are unable to respond to
cytokines that direct their differentiation
(19). The differentiation of naïve CD4 T
cells into Th1 and Th2 subsets, requires
mTORC1 and mTORC2 signaling, respec-
tively. Loss of mTORC1 signaling in CD4
T cells blocks their ability to upregulate
T-bet in the presence of IL-12 (20). IL-
12 mediated mTORC1 signaling in CD8
T cells sustains the expression of T-bet
and promotes differentiation into effector
cells (21). Moreover, inhibiting mTORC1
increases the expression of Eomes and
skews memory CD8 T cells toward IL-
15 dependence (17). CD4 T cells that
lack mTORC2 signaling have diminished
responses to IL-4 and IL-13. Less is known
about the function of mTORC2 in CD8 T
cells. However, given CD4 and CD8 T cells’
shared dependence on the same cytokines
or cytokine signaling pathways for their dif-
ferentiation, the role of mTORC2 in CD8 T
cell function will be an important direction
for future study.
ARE TRM REQUIRED FOR PROTECTION?
A major question is whether TRM posi-
tioned at sites of exposure are critical to
protect against local re-exposure. The pres-
ence of TRM can provide local protection
(3). However, circulating memory CD8 T
cells can migrate into barrier tissues upon
re-challenge and provide protection. How-
ever, antigen must first make its way to
mucosal draining lymph nodes in order
to prime circulating memory CD8 T cells
and recruit them to infected tissues. Due
to their proximity to infected tissue TRM
may be able to respond a pathogen expo-
sure more rapidly than circulating mem-
ory CD8 T cells (22). The mucosa is the
major route of entry for HIV infection.
Within a few hours to days after expo-
sure, HIV can breach the mucosal barrier,
infect resting CD4 T cells, and presum-
ably establish latent virus reservoirs (23). In
non-human primate models of infection,
the latent reservoir is seeded rapidly some-
time during the first 3 days of infection
creating a big challenge for the immune
system (24). The time required for circu-
lating memory CD8 T cells to mount a
response may not be quick enough to pre-
vent the establishment of HIV infection.
It is now evident that eliminating infected
founder cell populations in the area of ini-
tial HIV entry is a critical requirement for
the immune system to provide protection.
Robust TRM responses at the portal of HIV
entry may be critical component. Whether
TRM can directly kill local infected cells
is not explicitly known. The surface area
of the mucosa barrier is immense and it
is estimated that for every TRM cell there
could be tasked to survey as many as
~103 cells (25). Therefore, it is important
to know the concentration of TRM that
would constitute a critical mass to pro-
vide protection. However, recent work has
shown that TRM may do more than kill
infected cells. TRM can rapidly respond to
local challenge and recruit new antigen-
specific memory CD8 T cells from the
circulation as well as bystander cell pop-
ulations (26). Moreover, TRM can acti-
vate neighboring NK cells and B cells by
providing a local source of IL-2, IFN-γ,
and TNF-α (27). Collectively, these recent
findings suggest that TRM could provide
protection not only by killing of infected
cells in barrier tissues, but also by taking
part in pathogen sensing and initiation of
the immune response. Thus it is important
to know whether vaccine prime-boost reg-
imens, which can generate large numbers
of TRM, will ultimately lead to protection
against mucosa-acquired infections such as
HIV and HSV.
MANIPULATING TRM FOR CLINICAL
BENEFIT
The observation that upon reactivation
TRM are capable of inducing activation of
innate cells and even protecting against an
antigenically unrelated pathogen may have
broader implications for vaccine design
(27). It is understood that local priming
of CD8 T cells or priming within mucosa
draining lymph nodes can generate effector
CD8 T cells that can become TRM. Build-
ing vaccines that favor priming at these
tissue sites and the establishment of long-
lived TRM, while challenging, is important,
and may include the following strategies.
Orally administered vaccines can induce
CD8 T cells that accumulate within tissues
such as the female reproductive tract and
small intestine of the gastrointestinal tract,
while attractive the longevity and func-
tional attributes of the memory cells gen-
erated from this approach need to be fur-
ther elucidated (28). Prime-boost strate-
gies using local challenge potentially can
increase the number of TRM to a level
that can provide protection. Identifying
key regulators of TRM formation, as can-
didate adjuvants to more traditional vac-
cine strategies, in order to re-direct primed
effectors to mucosal tissues to generate
increased numbers of TRM. However, the
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ability of these re-positioned TRM to persist
like their counterparts that are generated
in situ is still an area of research that war-
rants further investigation. On the other
hand, CD8 TRM cells may also play a cen-
tral role in tissue destruction in organ-
specific autoimmune disorders. The same
factors that are important for the genera-
tion of TRM may be potential targets for
blocking pathogenic CD8 T cell responses
in the small intestine of patients with
celiac disease. Our findings that low-doses
of rapamycin, a pharmacologic mTOR
inhibitor, blocked the accumulation of
CD8 T cells within the intestinal mucosa
suggest the mTOR pathway as a candidate
for therapeutic intervention (14). More-
over, we used a model of T cell medi-
ated enterocyte destruction that may have
some similarities to celiac disease patho-
genesis. Using this model, we demonstrated
that rapamycin was capable of blocking
the accumulation of CD8 T cells specific
for antigen expressed exclusively within the
small intestine. In this model, the autoim-
munity becomes fatal upon addition of
systemic inflammation and the adminis-
tration of low-dose rapamycin reversed
intestinal destruction and enhanced sur-
vival. For tumor immunity one hurdle is
positioning enough functional CD8 T cells
within the tumor milieu. Interestingly, a
small population of memory CD8 T cells
has been identified in the spleen and lymph
nodes that share characteristics of TRM in
that they do not re-circulate, and express
CD69 (29). It is of significant interest to
determine if an equivalent population of
TRM populates the tumor and if so how to
manipulate these cells to the point where
they have a negative impact on tumor
growth.
ACKNOWLEDGMENTS
This research was supported by the
National Institutes Health Grants
1R21AI095673-01A1 (Amanda L. Marzo),
the Rush Brian Piccolo Cancer Research
Fund # 62241 (Amanda L. Marzo), and
the Chicago Developmental Center for
AIDS Research (D-CFAR), an NIH funded
program (P30 AI 082151), which is sup-
ported by the following NIH Institutes
and Centers (NIAID, NCI, NIMH, NIDA,
NICHD, NHLBI, and NCCAM) (Amanda
L. Marzo).
REFERENCES
1. Cauley LS, Lefrancois L. Guarding the perimeter:
protection of the mucosa by tissue-resident mem-
ory T cells. Mucosal Immunol (2013) 6(1):14–23.
doi:10.1038/mi.2012.96
2. Masopust D, Choo D, Vezys V, Wherry EJ,
Duraiswamy J, Akondy R, et al. Dynamic T cell
migration program provides resident memory
within intestinal epithelium. J Exp Med (2010)
207(3):553–64. doi:10.1084/jem.20090858
3. Gebhardt T, Wakim LM, Eidsmo L, Reading PC,
Heath WR, Carbone FR. Memory T cells in
nonlymphoid tissue that provide enhanced local
immunity during infection with herpes simplex
virus. Nat Immunol (2009) 10(5):524–30. doi:10.
1038/ni.1718
4. Shin H, Iwasaki A. Tissue-resident memory T cells.
Immunol Rev (2013) 255(1):165–81. doi:10.1111/
imr.12087
5. Masopust D, Schenkel JM. The integration of T
cell migration, differentiation and function. Nat
Rev Immunol (2013) 13(5):309–20. doi:10.1038/
nri3442
6. Iwata M, Hirakiyama A, Eshima Y, Kagechika H,
Kato C, Song SY. Retinoic acid imprints gut-
homing specificity on T cells. Immunity (2004)
21(4):527–38. doi:10.1016/j.immuni.2004.08.011
7. Mackay LK, Rahimpour A, Ma JZ, Collins N,
Stock AT, Hafon ML, et al. The developmen-
tal pathway for CD103(+)CD8+ tissue-resident
memory T cells of skin. Nat Immunol (2013)
14(12):1294–301. doi:10.1038/ni.2744
8. Sheridan BS, Pham QM, Lee YT, Cauley LS, Pud-
dington L, Lefrancois L. Oral infection drives a
distinct population of intestinal resident memory
CD8(+) T cells with enhanced protective func-
tion. Immunity (2014) 40(5):747–57. doi:10.1016/
j.immuni.2014.03.007
9. Masopust D, Vezys V, Wherry EJ, Barber DL,
Ahmed R. Cutting edge: gut microenviron-
ment promotes differentiation of a unique
memory CD8 T cell population. J Immunol
(2006) 176(4):2079–83. doi:10.4049/jimmunol.
176.4.2079
10. Klonowski KD, Williams KJ, Marzo AL, Blair
DA, Lingenheld EG, Lefrancois L. Dynamics
of blood-borne CD8 memory T cell migration
in vivo. Immunity (2004) 20(5):551–62. doi:10.
1016/S1074-7613(04)00103-7
11. Sathaliyawala T, Kubota M, Yudanin N, Turner
D, Camp P, Thome JJ, et al. Distribution and
compartmentalization of human circulating and
tissue-resident memory T cell subsets. Immunity
(2013) 38(1):187–97. doi:10.1016/j.immuni.2012.
09.020
12. Skon CN, Lee JY, Anderson KG, Masopust
D, Hogquist KA, Jameson SC. Transcriptional
downregulation of S1pr1 is required for the
establishment of resident memory CD8+ T cells.
Nat Immunol (2013) 14(12):1285–93. doi:10.1038/
ni.2745
13. Pollizzi KN, Powell JD. Integrating canonical and
metabolic signalling programmes in the regula-
tion of T cell responses. Nat Rev Immunol (2014)
14(7):435–46. doi:10.1038/nri3701
14. Sowell RT, Rogozinska M, Nelson CE, Vezys V,
Marzo AL. Cutting edge: generation of effector
cells that localize to mucosal tissues and form resi-
dent memory CD8 T cells is controlled by mTOR.
J Immunol (2014) 193(5):2067–71. doi:10.4049/
jimmunol.1400074
15. Stonier SW, Schluns KS. Trans-presentation: a
novel mechanism regulating IL-15 delivery and
responses. Immunol Lett (2010) 127(2):85–92. doi:
10.1016/j.imlet.2009.09.009
16. Marcais A, Cherfils-Vicini J, Viant C, Degouve S,
Viel S, Fenis A, et al. The metabolic checkpoint
kinase mTOR is essential for IL-15 signaling dur-
ing the development and activation of NK cells.
Nat Immunol (2014) 15(8):749–57. doi:10.1038/
ni.2936
17. Li Q, Rao RR, Araki K, Pollizzi K, Odunsi
K, Powell JD, et al. A central role for mTOR
kinase in homeostatic proliferation induced CD8+
T cell memory and tumor immunity. Immunity
(2011) 34(4):541–53. doi:10.1016/j.immuni.2011.
04.006
18. Sanjabi S, Mosaheb MM, Flavell RA. Opposing
effects of TGF-beta and IL-15 cytokines con-
trol the number of short-lived effector CD8+ T
cells. Immunity (2009) 31(1):131–44. doi:10.1016/
j.immuni.2009.04.020
19. Delgoffe GM, Kole TP, Zheng Y, Zarek PE,
Matthews KL, Xiao B, et al. The mTOR kinase
differentially regulates effector and regulatory
T cell lineage commitment. Immunity (2009)
30(6):832–44. doi:10.1016/j.immuni.2009.04.014
20. Delgoffe GM, Pollizzi KN, Waickman AT, Heikamp
E, Meyers DJ, Horton MR, et al. The kinase
mTOR regulates the differentiation of helper T
cells through the selective activation of signaling
by mTORC1 and mTORC2. Nat Immunol (2011)
12(4):295–303. doi:10.1038/ni.2005
21. Rao RR, Li Q, Odunsi K, Shrikant PA. The mTOR
kinase determines effector versus memory CD8+ T
cell fate by regulating the expression of transcrip-
tion factors T-bet and eomesodermin. Immunity
(2010) 32(1):67–78. doi:10.1016/j.immuni.2009.
10.010
22. Masopust D, Picker LJ. Hidden memories: front-
line memory T cells and early pathogen intercep-
tion. J Immunol (2012) 188(12):5811–7. doi:10.
4049/jimmunol.1102695
23. Haase AT. Targeting early infection to pre-
vent HIV-1 mucosal transmission. Nature (2010)
464(7286):217–23. doi:10.1038/nature08757
24. Whitney JB, Hill AL, Sanisetty S, Penaloza-
MacMaster P, Liu J, Shetty M, et al. Rapid seed-
ing of the viral reservoir prior to SIV viraemia in
rhesus monkeys. Nature (2014) 512(7512):74–7.
doi:10.1038/nature13594
25. Casey KA, Fraser KA, Schenkel JM, Moran A,
Abt MC, Beura LK, et al. Antigen-independent
differentiation and maintenance of effector-like
resident memory T cells in tissues. J Immunol
(2012) 188(10):4866–75. doi:10.4049/jimmunol.
1200402
26. Schenkel JM, Fraser KA, Vezys V, Masopust
D. Sensing and alarm function of resident
memory CD8(+) T cells. Nat Immunol (2013)
14(5):509–13. doi:10.1038/ni.2568
27. Schenkel JM, Fraser KA, Beura LK, Pauken KE,
Vezys V, Masopust D. T cell memory. Resi-
dent memory CD8 T cells trigger protective
www.frontiersin.org February 2015 | Volume 6 | Article 38 | 3
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sowell and Marzo Tissue resident memory and mTOR
innate and adaptive immune responses. Science
(2014) 346(6205):98–101. doi:10.1126/science.
1254536
28. Zhu Q, Talton J, Zhang G, Cunningham T,
Wang Z, Waters RC, et al. Large intestine-targeted,
nanoparticle-releasing oral vaccine to control
genitorectal viral infection. Nat Med (2012)
18(8):1291–6. doi:10.1038/nm.2866
29. Schenkel JM, Fraser KA, Masopust D. Cutting
edge: resident memory CD8 T cells occupy
frontline niches in secondary lymphoid organs.
J Immunol (2014) 192(7):2961–4. doi:10.4049/
jimmunol.1400003
Conflict of Interest Statement: The Associate Editor,
Kimberly Sue Schluns, declares that despite having col-
laborated with author Ryan T. Sowell in the past 2 years,
there has been no conflict of interest during the han-
dling of this manuscript. The authors declare that the
research was conducted in the absence of any commer-
cial or financial relationships that could be construed
as a potential conflict of interest.
Received: 09 December 2014; accepted: 20 January 2015;
published online: 05 February 2015.
Citation: Sowell RT and Marzo AL (2015) Resident-
memory CD8 T cells and mTOR: generation, protection,
and clinical importance. Front. Immunol. 6:38. doi:
10.3389/fimmu.2015.00038
This article was submitted to Immunological Memory, a
section of the journal Frontiers in Immunology.
Copyright © 2015 Sowell and Marzo. This is an open-
access article distributed under the terms of the Creative
Commons Attribution License (CC BY). The use, dis-
tribution or reproduction in other forums is permitted,
provided the original author(s) or licensor are credited
and that the original publication in this journal is cited,
in accordance with accepted academic practice. No use,
distribution or reproduction is permitted which does not
comply with these terms.
Frontiers in Immunology | Immunological Memory February 2015 | Volume 6 | Article 38 | 4
